Literature DB >> 34739688

Galactose specific lectins from prostate tissue with different pathologies: biochemical and cellular studies.

Elene Davitashvili1, George Burjanadze2, Marine Koshoridze2, Nana Koshoridze2, Tamar Tsertsvadze3, Nunu Mitskevich3, Omar Tsintsadze4, Guram Karazanashvili5, Revaz Solomonia6.   

Abstract

BACKGROUND: Galectins-galactose-specific lectins are involved in various types of cell activities, including apoptosis, cell cycle regulation, inflammation and cell transformation. Galectins are implicated in prostate malignat transformation. It is not known yet if prostate glands with different grade of pathologies are expressing different galectins and if these galectins express different effects on the cell viability.
METHODS: Cytosolic galactose-spesific lectin fractions from prostate tissue with different diagnosis were purified by affinity chromatography and analyzed by electrophoresis in polyacrylamide gel electrophoresis with sodium dodecyl sulphate. The lectin effects in a source-dependent maner were studied on cell viability on peripheral lymphocytes by MTT reduction method and on apoptosis by flow cytometry method.
RESULTS: Affinity purified galactose-specific lectins fractions from normal and pathological tissue samples are characterized with different protein composition and they express different effects on cell viability and apoptosis.
CONCLUSION: The effects of cytosolic galactose-specific lectins depend on the source of lectin fraction (glandular tissue disease). We suppose that the released cytosolic galectins from prostatic high grade intraepithelial neoplasia and adenocarcinoma tissue could suppress the immune status of the host patients.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Apoptosis; Cells survival viability; Gland diseases; Prostate galactose-specific lectins

Mesh:

Substances:

Year:  2021        PMID: 34739688     DOI: 10.1007/s11033-021-06894-w

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  16 in total

1.  MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets.

Authors:  Juan C Stockert; Alfonso Blázquez-Castro; Magdalena Cañete; Richard W Horobin; Angeles Villanueva
Journal:  Acta Histochem       Date:  2012-02-15       Impact factor: 2.479

Review 2.  Galectins in apoptosis.

Authors:  Daniel K Hsu; Ri-Yao Yang; Fu-Tong Liu
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

Review 3.  Galectins as modulators of tumour progression.

Authors:  Fu-Tong Liu; Gabriel A Rabinovich
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

Review 4.  A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics.

Authors:  Haike Ghazarian; Brian Idoni; Steven B Oppenheimer
Journal:  Acta Histochem       Date:  2010-03-02       Impact factor: 2.479

Review 5.  The sugar code: functional lectinomics.

Authors:  Hans-Joachim Gabius; Sabine André; Herbert Kaltner; Hans-Christian Siebert
Journal:  Biochim Biophys Acta       Date:  2002-09-19

Review 6.  Role of glycosylation in development.

Authors:  Robert S Haltiwanger; John B Lowe
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

7.  Unconventional secretion of fibroblast growth factor 2 and galectin-1 does not require shedding of plasma membrane-derived vesicles.

Authors:  Claudia Seelenmeyer; Carolin Stegmayer; Walter Nickel
Journal:  FEBS Lett       Date:  2008-03-25       Impact factor: 4.124

8.  High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancer.

Authors:  Debra L Zynger; Ximing Yang
Journal:  Int J Clin Exp Pathol       Date:  2008-12-22

9.  Rapid, simultaneous measurement of DNA, protein, and cell volume in single cells from large mammalian cell populations.

Authors:  H A Crissman; J A Steinkamp
Journal:  J Cell Biol       Date:  1973-12       Impact factor: 10.539

Review 10.  Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.

Authors:  Diego J Laderach; Lucas Gentilini; Felipe M Jaworski; Daniel Compagno
Journal:  Prostate Cancer       Date:  2013-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.